Advanced searches left 3/3

Carcinomatosis Peritoneal - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 September 2022

* If you want to update the article please login/register

Engineering Alendronate-Composed Iron Nanochelator for Efficient Peritoneal Carcinomatosis Treatment.

In addition, cancer cells also have a high demand for iron in their formation, invasion, and metastasis processes. CaALN nanoparticles selectively accumulate in tumor tissues, resulting in significant reduction of tumor formation and ascites formation in an intraperitoneal disseminated mouse model using the human ovarian cancer cells SKOV3. The mean survival time of SKOV3-bearing mice in the treatment group has been increased from 33 to 90 d, according to these findings, the alendronate-originated iron chelator may be a safe therapy for the treatment of peritoneal carcinomatosis.

Source link: https://europepmc.org/article/MED/36057999


Case Report: A rare presentation of prostate cancer with peritoneal carcinomatosis and malignant ascites complicated by tumor lysis syndrome

Background: In the literature, only 32 cases of prostate cancer with peritoneal carcinomatosis and ascites have been reported. We present the first reported case of prostate cancer with peritoneal carcinomatosis and malignant ascites in whose care was complicated by tumor lysis syndrome as well as a literature review examining similar situations. Case description We present the following case: A 78-year-old retired Caucasian male with recurrent metastatic prostate cancer and malignant ascites. Conclusions: Ascites in prostate cancer patients who experience occlusion are associated with worse prognosis and non-ascitic variants. Ascitic fluid prostate specific antigen testing may help with the diagnosis of malignant ascites in cases of diagnostic uncertainty. Patients with advanced disease may be able to benefit from combined hormonal and cytotoxic therapies. Patients with tumor lysis syndrome in prostate cancer patients can be identified as patients in whom prophylaxis might be helpful.

Source link: https://europepmc.org/article/PPR/PPR533685


Circulating Tumor DNA is Unreliable to Detect Somatic Gene Alterations in Gastrointestinal Peritoneal Carcinomatosis.

The amount of ctDNA detected in plasma is influenced by age, tumor burden, and tumor vascularization. We hypothesized that peritoneal carcinomatosis is associated with reduced ctDNA levels than other metastatic sites in GI cancers due to the plasma-peritoneal barrier. Methods We conducted a retrospective review of patients with stage II-IV GI cancers treated at our hospital between 2015 and 2020 using available panel-based ctDNA results. We compared the estimated maximum variant allele frequency of somatic mutations across metastatic sites. The 279 patients with GI cancers had stage IV disease, and 212 had stage IV disease. PC was associated with lower ctDNA levels in patients with stage IV disease, regardless of the primary tumor site. Conclusions PC of GI origins is associated with significantly lower ctDNA levels in comparison to visceral metastasis.

Source link: https://europepmc.org/article/MED/35980549

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions